About one in nine Americans age 65 and older has Alzheimer’s disease, and the costs associated with caring for these patients is expected to reach more than $200 billion this year. With a rapidly aging demographic, the expenses are growing like weeds.
The costs to our healthcare system, and patients’ families, are rising, but so is our understanding of the disease. In a nutshell, investigators are familiar with “clutter” the disease creates inside the brain, and the most promising approaches aim to continually clean up smaller messes before they become troublesome, or preventing little messes from occurring in the first place. Recently published research suggests marijuana-derived cannabinoids may play a role along these lines as well.
No single drug has been able to safely and effectively slow the disease’s progression, and experts in the field believe a combination of therapies will